Home LiteratureArticle Details
PMID: 1596594 Published · ppublish English Journal Article Review

Current drug therapy for Parkinson's disease. A review.

Drugs & aging ·Vol. 2 ·No. 2 ·1992-00-00 ·Pages 112-24

Coleman RJ

Abstract

The impact of neuropharmacology has been greatest in 2 areas of clinical treatment: epilepsy and Parkinson's disease. This article covers the drug treatment of Parkinson's disease, a condition which characteristically affects the elderly population. The 5 drugs or groups of drugs used in the treatment of Parkinson's disease are: (a) anticholinergic drugs; (b) amantadine; (c) levodopa plus a peripheral decarboxylase inhibitor; (d) dopamine agonists; and (e) selegiline. Levodopa is still the most effective anti-Parkinsonian drug for most patients and is often combined with selegiline which may retard the rate of disease progression. The early use of dopamine agonists (such as bromocriptine) may prevent the subsequent development of response fluctuations. Once fluctuations have developed, they may be helped by the use of slow release levodopa preparations and, in the most severe cases, subcutaneous apomorphine.

MeSH Terms
Humans Parkinson Disease/drug therapy
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Coleman R J
Department of Neurology, St James's University Hospital, Leeds, England.
References (67)
67 references, click to expand
  1. Lisuride in parkinsonism.
    Ann Neurol. 1981 Jan;9(1):48-52 PMID: 7212665
  2. Parkinsonism: onset, progression and mortality.
    Neurology. 1967 May;17(5):427-42 PMID: 6067254
  3. Long-term study of pergolide in Parkinson's disease.
    Neurology. 1985 Mar;35(3):296-9 PMID: 3974887
  4. Dopamine: release from the brain in vivo by amantadine.
    Science. 1971 Oct 22;174(4007):408-10 PMID: 5111993
  5. Long-term experience with pergolide therapy of advanced parkinsonism.
    Neurology. 1985 May;35(5):738-42 PMID: 3887213
  6. Dopamine (3-hydroxytyramine) and brain function.
    Pharmacol Rev. 1966 Jun;18(2):925-64 PMID: 5328389
  7. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):422-6 PMID: 4838913
  8. Comparison of pergolide and bromocriptine therapy in parkinsonism.
    Neurology. 1983 Aug;33(8):1009-14 PMID: 6348585
  9. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
    Arch Neurol. 1989 Oct;46(10):1052-60 PMID: 2508608
  10. Amantadine in the treatment of Parkinson's disease.
    JAMA. 1969 May 19;208(7):1168-70 PMID: 5818715
  11. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
    J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):207-12 PMID: 2649640
  12. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
    Ann Neurol. 1986 May;19(5):487-92 PMID: 2940960
  13. EFFECTS OF TRIHEXYPHENIDYL HYDROCHLORIDE (ARTANE) ON PARKINSON'S DISEASE.
    Neurology. 1964 Jan;14:13-23 PMID: 14112442
  14. Control of on/off phenomenon by continuous intravenous infusion of levodopa.
    Neurology. 1984 Sep;34(9):1131-6 PMID: 6540399
  15. Clozapine. A novel antipsychotic agent.
    N Engl J Med. 1991 Mar 14;324(11):746-54 PMID: 1671793
  16. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
    Clin Neuropharmacol. 1988 Feb;11(1):36-44 PMID: 3349496
  17. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
    Neurology. 1990 May;40(5):832-4 PMID: 1970427
  18. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier.
    J Neurochem. 1975 Dec;25(6):837-42 PMID: 1206400
  19. Lisuride in parkinsonism.
    Neurology. 1981 Apr;31(4):371-6 PMID: 7194429
  20. Apomorphine in Parkinson's disease.
    Trans Am Neurol Assoc. 1951;56:251-3 PMID: 14913646
  21. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
    J Neural Transm. 1985;64(2):113-27 PMID: 3935752
  22. Cholinergic-anticholinergic antagonism in parkinsonism.
    Arch Neurol. 1967 Aug;17(2):124-36 PMID: 4382112
  23. Young onset Parkinson's disease.
    Mov Disord. 1987;2(2):73-91 PMID: 3504266
  24. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
    Neurology. 1982 Jan;32(1):69-72 PMID: 7033825
  25. Present views on the mode of action of acetylcholine in the central nervous system.
    Physiol Rev. 1945 Oct;25:596-42 PMID: 21004450
  26. The promise and limitations of controlled-release oral levodopa administration.
    Clin Neuropharmacol. 1989 Jun;12(3):147-66 PMID: 2663145
  27. Bromocriptine and lisuride in Parkinson disease.
    Ann Neurol. 1983 Jan;13(1):44-7 PMID: 6830164
  28. Domperidone and Parkinson's disease.
    Clin Neuropharmacol. 1986;9(6):517-32 PMID: 3542205
  29. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Science. 1989 Aug 4;245(4917):519-22 PMID: 2502843
  30. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Eur Neurol. 1987;27 Suppl 1:126-34 PMID: 3428306
  31. DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
    Adv Neurol. 1984;40:497-502 PMID: 6421112
  32. Selegiline in the early and late phases of Parkinson's disease.
    J Neural Transm Suppl. 1987;25:105-13 PMID: 3123597
  33. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Neurology. 1985 May;35(5):749-51 PMID: 3990974
  34. Livedo reticularis in patients with parkinsonism receiving amantadine.
    JAMA. 1970 Jun 1;212(9):1522-3 PMID: 5467552
  35. Further studies on the mode of action of amantadine.
    Acta Pharmacol Toxicol (Copenh). 1971;30(3):161-71 PMID: 5171936
  36. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
    Neurology. 1988 Jul;38(7):1143-6 PMID: 3290706
  37. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease.
    Neurology. 1974 Oct;24(10):912-9 PMID: 4606107
  38. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Nature. 1984 Oct 4-10;311(5985):467-9 PMID: 6332989
  39. The comparative value of amantadine and levodopa.
    Postgrad Med J. 1972 Jun;48(560):354-8 PMID: 4558895
  40. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Neurology. 1989 Mar;39(3):336-9 PMID: 2927639
  41. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
    Drugs Aging. 1991 May;1(3):228-48 PMID: 1794016
  42. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Clin Neuropharmacol. 1988 Apr;11(2):174-9 PMID: 3378226
  43. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
    Drugs. 1990 Mar;39(3):491-506 PMID: 2184010
  44. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
    Ann Neurol. 1980 Dec;8(6):558-63 PMID: 6260009
  45. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.
    Am J Physiol. 1971 Dec;221(6):1629-39 PMID: 5124307
  46. Bromocriptine and dopamine receptor stimulation.
    Br J Clin Pharmacol. 1976 Dec;3(6):977-82 PMID: 22216518
  47. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease.
    N Engl J Med. 1985 Sep 19;313(12):724-8 PMID: 4033697
  48. The hydrodynamically balanced system: a novel principle of controlled drug release.
    Eur Neurol. 1987;27 Suppl 1:21-7 PMID: 3322836
  49. Pharmacokinetics of levodopa.
    Clin Neuropharmacol. 1984;7(1):35-49 PMID: 6367973
  50. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease.
    Lancet. 1986 Mar 1;1(8479):467-70 PMID: 2869209
  51. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.
    Brain. 1984 Jun;107 ( Pt 2):487-506 PMID: 6722513
  52. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.
    Clin Neuropharmacol. 1986;9(5):430-9 PMID: 3768865
  53. The impact of treatment with levodopa on Parkinson's disease.
    Q J Med. 1980;49(195):283-93 PMID: 7465763
  54. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.
    Neurology. 1987 May;37(5):826-8 PMID: 3574685
  55. Enhanced response to low doses of levodopa after withdrawal from chronic treatment.
    Neurology. 1972 May;22(5):520-5 PMID: 4673448
  56. Anticholinergic and membrane activities of amantadine in neuromuscular transmission.
    Nature. 1976 Nov 4;264(5581):76-9 PMID: 187945
  57. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020-3 PMID: 7334388
  58. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96-101 PMID: 2313313
  59. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):936-41 PMID: 4772727
  60. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rev Neurol (Paris). 1982;138(5):401-8 PMID: 7146724
  61. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    N Engl J Med. 1984 Feb 23;310(8):483-8 PMID: 6694694
  62. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
    Lancet. 1976 Feb 7;1(7954):292-6 PMID: 55599
  63. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Neurology. 1987 Oct;37(10):1607-12 PMID: 3658164
  64. Levodopa in Parkinsonism: the effects of withdrawal of anticholinergic drugs.
    Br Med J. 1971 May 29;2(5760):487-91 PMID: 5579489
  65. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.
    Drugs. 1982 Nov;24(5):360-400 PMID: 6756878
  66. Aromatic amino acids and modification of parkinsonism.
    N Engl J Med. 1967 Feb 16;276(7):374-9 PMID: 5334614
  67. Effect of deprenyl on the progression of disability in early Parkinson's disease.
    N Engl J Med. 1989 Nov 16;321(20):1364-71 PMID: 2509910
Article Info
Journal
Drugs & aging
Abbr.
Drugs Aging
ISSN
1170-229X
DOI
10.2165/00002512-199202020-00005
Published
1992-00-00
Pages
112-24
Language
English
Region
New Zealand
NLM ID
9102074
Subset
IM
External Links
PubMed source DOI: 10.2165/00002512-199202020-00005 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2